These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 20520837)

  • 1. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26.
    Fletcher MA; Zeng XR; Maher K; Levis S; Hurwitz B; Antoni M; Broderick G; Klimas NG
    PLoS One; 2010 May; 5(5):e10817. PubMed ID: 20520837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD26/dipeptidyl peptidase IV: a comparative study of healthy persons and kidney transplant recipients before and early after transplantation.
    Leicht S; Shipkova M; Klett C; Gert H; Altrock E; Wilhelm J; Bolley R; Wollmeyer J; Ender A; Luz B; Olbricht C; Wieland E
    Clin Biochem; 2013 Oct; 46(15):1383-8. PubMed ID: 23608353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and Clinical Significance of Serum Dipeptidyl Peptidase IV Chronic Obstructive Pulmonary Disease.
    Chang XY; Yang Y; Jia XQ; Wang Y; Peng LN; Ai XH; Jiang CY; Guo JH; Wu TT
    Am J Med Sci; 2016 Mar; 351(3):244-52. PubMed ID: 26992252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis.
    Grujic M; Matic IZ; Crnogorac MD; Velickovic AD; Kolundzija B; Cordero OJ; Juranic Z; Prodanovic S; Zlatanovic M; Babic D; Damjanov N
    Clin Chem Lab Med; 2017 Jan; 55(1):73-81. PubMed ID: 27341562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Huth TK; Staines D; Marshall-Gradisnik S
    J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum.
    Ohnuma K; Saito T; Hatano R; Hosono O; Iwata S; Dang NH; Ninomiya H; Morimoto C
    J Clin Lab Anal; 2015 Mar; 29(2):106-11. PubMed ID: 24687574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD26/dipeptidyl peptidase IV (CD26/DPPIV) is highly expressed in peripheral blood of HIV-1 exposed uninfected female sex workers.
    Songok EM; Osero B; McKinnon L; Rono MK; Apidi W; Matey EJ; Meyers AF; Luo M; Kimani J; Wachihi C; Ball BT; Plummer FA; Mpoke S
    Virol J; 2010 Nov; 7():343. PubMed ID: 21108831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.
    Durinx C; Lambeir AM; Bosmans E; Falmagne JB; Berghmans R; Haemers A; Scharpé S; De Meester I
    Eur J Biochem; 2000 Sep; 267(17):5608-13. PubMed ID: 10951221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells.
    Tsuji T; Sugahara K; Tsuruda K; Uemura A; Harasawa H; Hasegawa H; Hamaguchi Y; Tomonaga M; Yamada Y; Kamihira S
    Int J Hematol; 2004 Oct; 80(3):254-60. PubMed ID: 15540901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors.
    Erić-Nikolić A; Matić IZ; Dorđević M; Milovanović Z; Marković I; Džodić R; Inić M; Srdić-Rajić T; Jevrić M; Gavrilović D; Cordero OJ; Juranić ZD
    Immunobiology; 2011 Aug; 216(8):942-6. PubMed ID: 21281985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase IV: serum activity and expression on lymphocytes in different hematological malignancies.
    Matić IZ; Đorđević M; Đorđić M; Grozdanić N; Damjanović A; Kolundžija B; Vidović A; Bila J; Ristić S; Mihaljević B; Tomin D; Milanović N; Ristić D; Purić M; Gavrilović D; Cordero OJ; Juranić ZD
    Leuk Lymphoma; 2013 Dec; 54(12):2701-6. PubMed ID: 23469960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
    Rivas JL; Palencia T; Fernández G; García M
    Front Immunol; 2018; 9():1028. PubMed ID: 29867995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus.
    Kobayashi H; Hosono O; Mimori T; Kawasaki H; Dang NH; Tanaka H; Morimoto C
    J Rheumatol; 2002 Sep; 29(9):1858-66. PubMed ID: 12233879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of biomarkers with health-related quality of life and history of stressors in myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Fenouillet E; Vigouroux A; Steinberg JG; Chagvardieff A; Retornaz F; Guieu R; Jammes Y
    J Transl Med; 2016 Aug; 14(1):251. PubMed ID: 27580693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
    Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Wong N; Ramos S; Staines D; Marshall-Gradisnik S
    BMC Immunol; 2015 Jun; 16():35. PubMed ID: 26032326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic abnormalities in chronic fatigue syndrome.
    Klimas NG; Salvato FR; Morgan R; Fletcher MA
    J Clin Microbiol; 1990 Jun; 28(6):1403-10. PubMed ID: 2166084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
    Brenu EW; van Driel ML; Staines DR; Ashton KJ; Ramos SB; Keane J; Klimas NG; Marshall-Gradisnik SM
    J Transl Med; 2011 May; 9():81. PubMed ID: 21619669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological abnormalities in patients with chronic fatigue syndrome.
    Tirelli U; Marotta G; Improta S; Pinto A
    Scand J Immunol; 1994 Dec; 40(6):601-8. PubMed ID: 7997849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
    Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
    BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26).
    Duke-Cohan JS; Morimoto C; Rocker JA; Schlossman SF
    J Biol Chem; 1995 Jun; 270(23):14107-14. PubMed ID: 7539799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.